BlueTheory Clinical Trials, a clinical research network company headquartered in Boston, Massachusetts has been partnering with pharmaceutical and CROs to bring treatments and devices to the market since its inception. Based on increased demands from BlueTheory’s over 30 aligned pharmaceutical and CRO strategic partners, BlueTheory has enhanced its site business model and is announcing its rebrand to BTC Network.
BTC Network has optimized its infrastructure to an owned and affiliated research site model. The BTC Network team has completed over 300 clinical research studies across a range of therapeutic indications with the goal of expediting study startup and enrollment while ensuring our research sites provide excellent clinical oversight and good quality data. Today, BTC Network has grown to represent 63 full service, multi-specialty clinical research sites across the U.S. and Canada. BTC Network is currently in the final stages of acquiring two additional clinical research sites with other acquisitions on the near horizon.
With increased demands from Pharmaceutical companies and CROs for BTC Network to enroll all of the patients for their upcoming study protocols, BTC’s experienced team has worked to optimize research site performance by utilizing a number of cutting-edge resources.
“By leveraging a number of centralized resources, all BTC Network sites have been able to streamline the start-up process and ultimately see faster rates of enrollment,” said Scott Palmese, director of Clinical Operations at BTC Network.
Alfred Peters, president at BTC Network, said, “Pharmaceutical companies and CROs do not have to view U.S. research facilities as a mom and pop industry. Our ability to offer centralized processes with one point of contact from start-up through enrollment for all of our sites with BTC Network¹s provided resources is critical to our success. Our resources include: contracts/budgets, receivable management, pharmaceutical relationship management, patient recruitment and retention, patient travel coordination, access to clinic patient populations, quality management team, centralized call center and many others. These resources put our research sites in the best possible position to understand therapeutic strengths and capabilities to exceed expectations on all clinical research studies.”
BTC Network works on behalf of leading pharmaceutical companies and CROs to excel in the identification, recruitment, and retention of patients. BTC Network’s number one focus is patient centricity. By working with BTC Network, sponsors and CROs have access to a fully integrated network of high performing and experienced sites with strong research infrastructures and access to large clinic populations, expediting enrollment.
Through the new BTC Network, sponsors will have access to:
BTC Network’s partnerships throughout the industry and streamlined processes from study start-up to close-out will lead to more cost-effective, yet higher quality, research studies for the industry.